Munro CE, Buckley R, Vannini P, DeMuro C, Sperling R, Rentz DM, Johnson K, Gathchel JR, Amariglio R. Longitudinal trajectories of participant- and study partner-rated cognitive decline, in relation to alzheimer's disease biomarkers and mood symptoms. Front Aging Neurosci. 2022 Jan 31;13:806432. doi: 10.3389/fnagi.2021.806432
Hiligsmann M, Dellaert BG, Dirksen CD, Watson V, Bours S, Goemaere S, Reginster JY, Roux C, McGowan B, Silke C, Whelan B, Diez-Perez A, Torres E, Papadakis G, Rizzoli R, Cooper C, Pearson G, Boonen A. Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. Rheumatology (Oxford). 2017 Jul 1;56(7):1167-76. doi: 10.1093/rheumatology/kex071
Hifinger M, Hiligsmann M, Ramiro S, Severens JL, Fautrel B, Watson V, Boonen A. Patient's preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists. Rheumatology (Oxford). 2017 Jan;56(1):68-76. doi: 10.1093/rheumatology/kew328
Glück S, Russell C, O'Shaughnessy J, McKenna EF, Hu S, Odom D, Blum JL. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast. 2013 Dec;22(6):1087-93. doi: 10.1016/j.breast.2013.08.016.
Keenan A-M, McKenna SP, Doward LC, Conaghan PC, Emery P, Tennant A. OAQoL: development and preliminary validation of a needs-based quality of life measure for osteoarthritis. Poster presented at the American College of Rheumatology 2007 Annual Scientific Meeting; April 2007. Chicago, IL. [abstract] Rheumatology (Oxford). 2007; 46:162-3.